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STUDIES ON THE REACTION OF HIGH-DOSE HYDROXOCOBALAMIN AND
ASCORBIC ACID WITH CARBON MONOXIDE: IMPLICATIONS FOR TREATMENT
OF CARBON MONOXIDE POISONING.
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Based upon experimental evidence from the 1970’s we proposed that a reduced
form of hydroxocobalamin should be capable of producing carbon dioxide (CO 2 ) from
carbon monoxide (CO) in blood, and that this conversion should be detectable. Using
resonance raman spectroscopy we demonstrated that a mixture of hydroxocobalamin
and ascorbic acid could create the reduced form of hydroxocobalamin. We used a
closed-loop circulation system with a hollow-fiber membrane oxygenator to produce
carboxyhemoglobin. Using sensitive gas monitoring equipment to the gas-out port of the

oxygenator we analyzed the CO and CO 2 concentrations coming from the oxygenator.
The mixture of hydroxocobalamin and ascorbic acid caused a 5-fold increase in the CO 2
concentration of the gas-out flow, in comparison to baseline and negative controls.
These findings offer initial support for the potential use of a mixture of
hydroxocobalamin and ascorbic acid as an injectable antidote for carbon monoxide
poisoning.

Introduction and Background:
1.1 Hypothesis:
Hydroxocobalamin (OHCbl) has been used in Europe as an antidote for cyanide
poisoning and smoke inhalation for over 40 years.1 Research from the 1970’s indicated
that a reduced form of OHCbl was capable of converting carbon monoxide (CO) into
carbon dioxide (CO 2 ).2 The authors recognized the potential clinical implications of this
finding but stated that they were unable to detect decarbonylation of carboxyhemoglobin
(COHgb) when reduced OHCbl (OHCbl2+) was added. Surprisingly, we have been
unable to find any additional publications on the interaction of OHCbl2+ with COHgb and
concluded that further investigations were warranted.
The formation of OHCbl2+ in solution may be accomplished with a multitude of
different reducing agents, however not all reducing agents are suitable for injection into
a living organism or approved for use in humans. Several potential reducing agents
were considered and evaluated during pilot studies and, ultimately, L-ascorbic acid was
chosen for this study. Ascorbic acid is a powerful reducing agent that is also non-toxic
even at relatively high-doses.3,4
We found that a mixture of OHCbl and ascorbic acid in deoxygenated normal
saline (herein referred to as “the antidote”) could produce the reduced form of OHCbl,
as demonstrated by characteristic changes on Resonance Raman spectroscopy.
Therefore we hypothesized that this mixture should be capable of producing CO 2 from
CO in blood. CO is typically removed from the body by the use of either high-flow
atmospheric or hyperbaric O 2 . The conversion of CO to CO 2 would be a novel approach
1

for CO detoxification. We determined that if this conversion were large enough to
produce a potentially clinically relevant effect then it should be detectable by monitoring
CO 2 generation from the blood using a closed-loop artificial circulation system.
1.2 CO Poisoning:
1.2.1 Magnitude of the Problem:
Carbon monoxide (CO) is a colorless, odorless, and tasteless gas that is formed
from incomplete combustion of hydrocarbons. CO poisoning is a major public health
concern, both in the United States and worldwide. CO may be encountered as a sole
toxicant such as in a suicide attempt using automobile exhaust, or as one of several
toxicants such as in smoke exposure during a fire. CO alone is responsible for 40,000
ED visits annually in the United States and at least 5000-6000 deaths each year.5–7 In
the “World Health Organization European Member States” there were 140,490 CO
related deaths reported between 1980-2008.8 These numbers only reflect those cases
where CO was the primary or only exposure. It is suspected that the actual incidence is
much greater since COHgb levels are not routinely tested and CO poisoning is often
mistaken for other illnesses.6 If one adds smoke inhalation to this (a major component
of which is CO), then the numbers increase significantly. In the United States, it is
estimated that 310,000-670,000 people are exposed to the toxic effects of smoke
inhalation in residential fires each year, and that 20,000-30,000 are reported as injured
or killed.9
While smoke inhalation represents the majority of most unintentional cases of
CO exposure, there are many others and the magnitude of these varies by both season
2

and location. Other sources include malfunctioning heaters or hot-water heaters,
improperly vented heating or cooking appliances (kerosene heaters, propane stoves,
charcoal grills, generators and automotive exhaust).6,10–12 Large-scale exposures often
occur in the setting of office buildings or gathering places where a heater or oil-burning
furnace malfunctions or leaks exhaust fumes into the HVAC system. Electrical wire
insulation has also been shown to produce significant amounts of CO when wires
overheat and begin to burn through the insulation. Natural disasters such as hurricanes,
tornadoes, and earthquakes have been shown to cause a dramatic rise in CO
poisonings immediately following the disaster, mainly due to fires, damaged electrical
wiring and improper use of gas-powered generators.11 Exposures can also occur in the
workplace and healthcare settings from improperly connected anesthesia circuits and
from exposure to compounds such as methylene chloride.13
1.2.2 Pathophysiology:
No matter the source, the effect of CO is the same. It diffuses rapidly across the
pulmonary epithelium and binds to the iron moiety of heme and other hemoproteins with
200-300 times the affinity of O 2 . The amount of carboxyhemoglobin (COHgb) that
develops is highly variable and depends upon the concentration of CO in the inhaled air,
the duration of exposure, heart rate, and the minute respiration. CO is endogenously
produced and is ubiquitous in nature. All humans have at least some amount of COHgb
in their blood, typically ranging from 1-3%. Smokers and those who live in large or
polluted urban environments can have concentrations from 5-15% at baseline!14 It is
believed that other sources of oxidative stress such as diabetes, chronic ulcers,
autoimmune disorders and critical illness may also lead to elevated levels of COHgb
3

that are above that of the normal population and several centers are actively studying
this phenomenon.15,16
Due to the binding chemistry of CO to hemoglobin (Hgb), it induces a
conformational change in the shape of Hgb that reduces the ability of the other three O 2
binding sites to off-load O 2 to the tissues. This is represented as a left-shift of the oxyhemoglobin dissociation curve. The combination of the left-shift of the oxy-hemoglobin
dissociation curve, as well as the presence of CO on sites that are normally occupied by
O 2 are believed to cause a decrease in tissue O 2 delivery resulting in a
hypoxic/ischemic form of injury, especially in O 2 sensitive tissues and watershed
vascular beds.
Beyond its impairment of O 2 delivery, it has been shown that CO is also capable
of binding numerous other hemoproteins in the body including myoglobin, the
cytochromes, and NADPH reductase among others. The exact extent to which binding
of these proteins plays a role in the toxic effects of CO remains controversial, but it
believed that at least 10-15% of the CO which is inhaled winds up in the extravascular
space bound to proteins like those mentioned above.17,18 Ultimately, it is felt that this
results in decreased O 2 utilization and mitochondrial dysfunction particularly in tissues
like the heart and brain, where dysfunction continues despite adequate O 2 delivery.19–21
The effects on the brain specifically, are referred to as delayed neurologic sequelae
(DNS) and/or prolonged neurologic sequelae (PNS). The exact mechanism of
DNS/PNS remains uncertain, but several recent studies have indicated that it may be a
result of brain lipid peroxidation that leads to an exaggerated immune response.22
These studies have implicated xanthine oxidoreductase as a potential mediator of this
4

lipid peroxidation but more data are needed.21 What has become clear in recent years is
that the neurologic injury subsequent to CO poisoning is distinct from a simple hypoxic
form of injury and cannot be attributed solely to the effects of CO upon hemoglobin or
oxidative phosphorylation.23–25
1.2.3 Clinical Presentation and Diagnosis:
Diagnosis of CO poisoning, particularly when it is unintentional, is often very
difficult.18,26 CO poisoning is not a condition that any one clinician is likely to encounter
on a routine basis except for those who specifically work in the fields of trauma, burn,
and emergency medicine. Unless a history of CO exposure is provided, CO poisoning
presents much like an acute viral illness. Headache (most common), malaise, nausea,
dizziness and (if the exposure is large enough) loss of consciousness are the most
frequently encountered signs and symptoms. The classic description of cherry-red
blood, or bright red skin or lips is rarely encountered except when the COHgb is
extremely high and is, therefore, not useful as a marker of CO toxicity.10,17,18
Unfortunately, due to the nonspecific nature of the signs and symptoms, CO poisoning
is often misdiagnosed. Since testing for COHgb is not routine, it must be requested by
the ordering clinician or it will be overlooked. The recent development of a rapid and
reliable device for noninvasive assessment of COHgb concentration may provide a
much needed breakthrough in the diagnosis of CO poisoning.27–29 Unfortunately, the
accuracy of these devices has been called into question repeatedly, with several studies
suggesting that while they may be beneficial as a routine screening tool in patients at
risk they are not a substitute for laboratory COHgb measurement.30,31 Any time a patient
is suspected of having CO toxicity it is recommended that a blood sample be sent for
5

oximetry analysis immediately and the patient should be placed on 100% O 2 by a nonrebreather mask. If a case of suspected CO poisoning is confirmed, then additional
tests should be ordered, including arterial blood gas (to check for acidosis), ECG (to
check for dysrhythmias) and cardiac biomarkers (to check for myocardial injury).
1.2.4 Complications:
As many as one-third of patients with CO poisoning will develop evidence of
acute myocardial injury.32 This has been shown to lead to a significant increase in
mortality, with these patients having three times the risk of death as their non-poisoned
counterparts.33 Again, the mechanism of this injury remains a subject of controversy and
intense research. The classic paradigm of hypoxic/ischemic injury is insufficient to
explain the disturbances that are seen. While it is likely that inhibition of cytochromes
and/or myocardial myoglobin play a role in this, several studies have shown that CO
may be capable of directly interacting with ion channels leading to arrhythmias and
contractile dysfunction of cardiac muscle.34–38
As previously mentioned, a second major complication of CO poisoning is the
development of DNS/PNS. Studies have shown that this can occur in up to 40% of
patients and can manifest up to 240 days following discharge from the hospital.39–43
Most often however, the symptoms of DNS/PNS arise within the first 30 days following
exposure, and the deficits typically persist for at least a year or more. Symptoms of
DNS/PNS include cognitive deficits, personality changes, focal neurologic deficits,
movement disorders and balance disorders. Surprisingly, the development of DNS/PNS
is only poorly associated with COHgb concentration.40 Patients who have lost
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consciousness at some point during or immediately following exposure have been
shown to be at the highest risk. Additional complications include acute lung injury, endorgan failure, metabolic acidosis, and (in pregnant women) fetal distress with a high
potential for fetal death.
1.2.5 Management
Presently, the only therapy for CO poisoning is the delivery of oxygen (O 2 ). This
can be subdivided into atmospheric pressure O 2 (i.e., normobaric or NBO) and highpressure O 2 (i.e., hyperbaric or HBO). NBO has the advantage that all hospitals and
many EMS providers are able to deliver NBO as soon as the diagnosis is made or
suspected. NBO can reduce the half-life of COHgb from 5 hours, down to about 60-90
minutes. HBO on the other hand can reduce the half-life of COHgb down to about 15-30
minutes. HBO has the advantage that (due to the high pressure) it can substantially
increase the solubility of O 2 in plasma, and thus increases the partial pressure of O 2 in
the blood from 0.3 mL/dL to around 6.0 mL/dL (depending upon the protocol used).
The primary indication for the use of HBO is in patients whose COHgb% is
greater than 25-40% and/or who show evidence of end-organ damage (i.e., acidosis,
renal dysfunction) ECG changes, or elevated cardiac biomarkers.18,39,44 The main goal
of HBO is to increase O 2 delivery to tissues via unbound O 2 dissolved in plasma,
restore Hgb to normal functioning as quickly as possible, and to prevent acute
myocardial injury and DNS/PNS. Unfortunately, despite a multitude of studies on the
efficacy of HBO over the past 30 years, the use of this therapy remains highly
controversial.45,46 This is in large part due to the lack of available facilities, difficulty of
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transferring patients, and the inability to access a patient quickly if they begin doing
poorly once they are in the chamber. The inadequacies of both NBO and HBO for
treating CO poisoning and preventing the sequelae of CO poisoning are the driving
forces behind trying to find a better way to treat this significant public health problem.47
1.3 Chemistry and History of CO:
The CO molecule is a carbon triple-bonded to monatomic oxygen (MW=28.01
g/mol) and is characterized by a bond length of 112.8 pm.48 There is a lone pair on both
the carbon and the oxygen, and very little charge separation between them. Thus, CO is
a relatively unreactive gas, with a b.p. of -191.5 °C. It has ten valence electrons, four
from the carbon and six from the oxygen (dipole moment 0.122 D). CO coordinates only
to main group elements that are strong electron acceptors. CO also forms stable
complexes with many transition metals in low oxidation states, especially those from
groups 6 to 11. This explains its reactivity with Heme (Iron, group 8), Cytochrome c
(Copper, Group 11), and potentially Vitamin B 12 (Cobalt, Group 9).
The French physiologist Claude Bernard presented one of the first documented
studies of CO, and its toxic effects on humans, in 1857 in a series of lectures that have
become one of the seminal works of the field of Toxicology.49 By the 1940’s it had been
demonstrated that the binding of CO to Hgb changes the shape of the oxyhemoglobin
dissociation curve to hyperbolic instead of sigmoid (i.e. a flattened and downward shift)
and shifts the curve to the left.50 This means that not only is the O 2 saturation of Hgb
lower in the presence of COHgb, but the unloading of O 2 from Hgb in the tissues is also
diminished.51 We now know that besides its interactions with heme, CO also binds to
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the mitochondrial heme protein cytochrome c oxidase, as well as microsomal
cytochrome P450 enzymes.52,53 Then in the 1950’s and 60’s CO was shown to be
formed endogenously by the degradation of Hgb via the enzyme heme oxygenase
(HO).54–57 Initially, it was felt that this was simply a byproduct of Hgb degradation
without a direct purpose.
1.4 Gaps in Current Understanding:
Douglas and Haldane are the most famous for their work on CO and its effects
on Hgb, a fact they came across while trying to better understand the reversible nature
of the binding of O 2 to Hgb.50,58 Their work in this area is still taught in medical schools
around the world and we shall herein refer to it as the “carboxyhemoglobin theory of CO
toxicity.” While the efforts of Douglas and Haldane were, and continue to be,
outstanding science, the question remains: is the primary source of toxicity for CO due
to the formation of COHgb and subsequent loss of adequate O 2 delivery to vital
tissues? The modern answer to this important question, based upon the work by a
number of experts in this field is a resounding, “No!”18,47,59
There is no question that CO binds to Hgb with an affinity somewhere between
200-300 times greater than that of O 2 .50 There is also no question that the binding of
CO to Hgb causes a leftward and downward shift of the COHgb dissociation curve,
lowering the O 2 carrying capacity of Hgb and causing Hgb to bind more tightly to
O 2 .50,58,60 There is however a very big question surrounding whether or not these
changes result in meaningfully diminished O 2 delivery to the tissues that need them for
aerobic respiration. Multiple studies have shown quite convincingly that except when the
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COHgb concentration exceeds 70-80%, or in situations where the poisoned individual is
in an environment deprived of O 2 or engaged in metabolically demanding activities, the
poisoned Hgb is still able to deliver an adequate supply of O 2 to tissues that need it
most.20,59,61,62 This is in part due to the fact that Hgb has a very large functional reserve
that we rarely ever tap into, and because the body is extremely efficient at altering the
dissociation curve in order to maximize O 2 delivery and extraction efficiency.62
These problems with the carboxyhemoglobin theory were noticed early on and,
indeed, Haldane’s own son sought to disprove the theory.60 One major problem which
was immediately apparent and remains to this day, is that the COHgb concentration of a
patient bears little or no relevance to the patients outcome or the severity of their
injury.45,63–66 This is particularly true in pregnant women who are exposed to CO. In
these cases, the effects on the fetus are even more variable, despite the fact that the
fetus is not inhaling CO directly.1,67 If the injury were due primarily to ischemia, as the
carboxyhemoglobin theory suggests, then a patients outcome and injury severity should
be a function of their COHgb%. In other words, as a patient’s COHgb% increases, so
too should the severity of their injury. Instead what we see is a wide variance in patient
presentation and outcomes across a wide range of COHgb values, even when other
confounding variables have been accounted for. Patients with “fatal” levels sometimes
survive and do fairly well, while others with only mild to moderate elevations of COHgb
may die or do very poorly, often suffering for years from neurologic and cardiac
complications.17,33,40,63 This points to the idea that some other process must be involved,
but it is one that scientists have had difficulty locating until recently.
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1.5 Therapeutic applications of CO and what that teaches us:
It was demonstrated in the late 1980s that both NO and CO, applied
exogenously, stimulated vessel relaxation.68 It was then shown that the mechanism for
this was through the second messenger guanylate cyclase system (a heme-containing
protein), which converts guanosine triphosphate (GTP) to cyclic-guanosine
monophosphate (cGMP).68,69 More than a mere curiosity, both of these gaseous
compounds are produced endogenously and on purpose, for it now appears that there
are vital functions carried out by these simple gases. Several very recent studies have
indicated that an impaired HO/CO system may be an underlying cause of vascular
resistance in diseases such as systemic and pulmonary hypertension among others.70–
72

These studies have indicated that while Heme Oxygenase-1 (HO-1) is present in all

mammalian cells, its expression is increased in cells subjected to conditions of
increased oxidative stress, which is the common denominator in the progression of
vascular dysfunction, cardiovascular disorders and inflammatory diseases.73–75 Rather
than being a cause of the damage, however, the HO-1/CO upregulation appears to be a
defensive and protective response by the cell.74,76–78
At physiologically relevant concentrations CO exhibits potent vasorelaxant effects
which are independent of NO and this allows for greater blood flow to tissues
undergoing stress.70,79,80 However, the effects of CO are not restricted to guanylate
cyclase activation. Other studies have demonstrated that CO directly effects the
opening of big-conductance calcium-activated potassium channels (B K Ca) which leads
to membrane hyperpolarization, thereby closing voltage-dependent Ca2+ channels, and
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reducing resting Ca2+ concentration of smooth muscle cells.38,81,82 The end result of this
process is vasodilation by smooth muscle relaxation.82
The effects of CO go far beyond vasorelaxation. A study in 2000 demonstrated
that low concentrations of CO gas (250 ppm) applied to murine macrophages or
administered directly to rodents, significantly reduced the inflammatory response to
lipopolysaccharide (LPS). The authors demonstrated that CO gas inhibited the
expression of pro-inflammatory cytokines (TNF-α, IL-1β) and increased the expression
of anti-inflammatory mediators such as IL-10 in response to LPS.83 The authors also
showed that CO mediated these anti-inflammatory effects through a pathway involving
mitogen-activated protein kinases (MAPK). Several other studies involving the use of
Carbon Monoxide Releasing Molecules (CORM’s), showed that these compounds were
able to down-regulate Matrix Metalloproteinase (MMP) expression and inhibit cartilage
degradation in arthritis models and alveolar macrophages.84–86 This makes sense since
MMP’s normally contain zinc which, although not technically a transition metal, shares
many properties in common with them and is a common moiety in many proteins.
CO also appears to have anti-apoptotic properties. CO has been shown in
several studies to prevent apoptosis in endothelial cells, vascular smooth muscle cells,
hepatocytes, and neurons.87–90 This effect appears to involve phosphorylation and
activation of p38 MAPK, although the precise mechanism has yet to be worked out.
There are several other biological substrates that have been discovered in recent years
and the list continues to grow.91,92 With so many endogenous functions of CO in the
body, is it any wonder that scientists have had difficulty determining the primary cause
of CO toxicity?
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Most of the research into treating this significant issue has focused on methods
of increasing O 2 delivery, either via high-pressure O 2 (hyperbaric oxygen therapy, HBO)
or through O 2 carrier compounds such as perfluorocarbons and other blood substitutes,
even including blood donation.18,93,94 Yet all of these therapies are based upon the belief
that CO toxicity is due to poisoned Hgb and insufficient O 2 delivery to vital organs. We
say belief because this is a point of view which has never in fact been definitively
proven, and recently the bulk of scientific evidence now suggests that this view is at the
very least incomplete.18,47 Furthermore, even if ischemia were a significant component
of CO poisoning there are many other, now well proven, physiologic processes that are
disrupted through CO overdose and which could (and should) be therapeutic
targets.18,47
1.6 Recent Developments and Their Implications:
There is a saying in pharmaceutical circles that says “the poison is in the dose”
(from Paracelsus, “the dose makes the poison”). Following the discovery of Nitric Oxide
as an endogenously produced gas with regulatory and cellular transmitter-like
properties, scientists began to look for other “gasotransmitters”.74,95,96 It turns out that
CO, is more than just a poison, it can actually be a medicine when given at extremely
low doses.78,83–86 Moreover, CO has been shown to be produced endogenously as a
cellular protectant by nearly every cell in our bodies when they are subjected to
situations of oxidative stress or injury.57,75–77,97,98 This discovery led scientists to
question if there were other natural functions of CO in the body beyond cellular
protection, in much the same way as there were for nitric oxide. What they have found
is that CO plays a major role in multiple cellular processes in almost every organ
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system, and in system-specific ways. These include interactions with soluble guanylate
cyclase, big-conductance potassium-gated calcium channels (B k Ca), sodium channels,
nitric oxide and nitric oxide synthase, mitochondria, cytochromes, NADPH oxidase, and
xanthine oxidase to name just a few, and the list is growing every day.21,24,34–
36,68,69,81,82,99,100

Of course, if CO plays an important regulatory role in all of these

pathways in a normal healthy individual, then it stands to reason that an overdose of CO
would result in a dysregulation of all of these pathways. Multiple studies have now
shown that this is exactly what happens and that this finally provides a logical
explanation for the extreme variability that is encountered in patients with this form of
poisoning.18,47,101–104 This also explains why O 2 (whether at high pressure or
atmospheric pressure) is such a poor solution for this injury. If CO were, indeed, a
simple case of ischemia, then high-flow, high-pressure O 2 would clearly be the best
choice.
The mechanism of CO’s toxicity has presumably been known for over 100 years
now, yet in all that time the treatment for this major public health concern has remained
relatively unchanged, except for the substitution of high-flow atmospheric O 2 with
hyperbaric O 2 as the standard of care.49,50,58 While patients and studies vary
significantly, it has been shown that normobaric 100% O 2 (NBO) can reduce the half-life
(t 1/2 ) of COHgb from about 5 hours (on room air) down to 60-90 minutes although the
exact time is still controversial.46,105–107 Hyperbaric O 2 (HBO) can reduce the t 1/2 even
further to approximately 15-30 minutes. Despite this, the use of HBO remains
controversial. HBO is expensive, has limited availability (typically requiring transfer of
critically ill patients), and has even been shown in some studies to increase morbidity
14

and the severity of neurologic sequelae.39,46,106,108,109 NBO is readily available and is
typically employed by first responders. However, even the reduction of the t 1/2 to 30
minutes is insufficient for the most severely poisoned patients (i.e., those in
cardiopulmonary collapse), nor does it always prevent neurologic sequelae.18,46,47,63,64 In
recent years, the use of both NBO and HBO is being increasingly called into
question.18,108
Under conditions of hypoxia or anoxia, neurons begin to suffer irreparable
damage in less than 10 minutes.110 It is, therefore, widely accepted that in the case of
CO poisoning, the time to treatment is far more important than the mode of treatment.
Even small delays in therapy administration can lead to significant increases in
morbidity and mortality.18,46,63 Yet the questions remain concerning which therapy is
best. Despite the seemingly innocuous nature of O 2 therapy, awareness is increasing of
the potential dangers of too much O 2 . Oxygen therapy has the potential for significant
free radical generation that can damage DNA, cell membranes, and even effect cellular
respiration.22 It has already been shown that CO also produces free radicals, leading to
cellular damage and that this may play a critical role in the mechanism of CO
toxicity.21,22,99,111–115 It is possible and even likely, that the addition of high
concentrations of O 2 to this scenario may further exacerbate the free radical damage
that is occurring in a patient suffering from CO poisoning.22 A second negative effect of
O 2 therapy is due to its action as a ventilatory stimulant. Hyperoxia can leads to
hyperventilation causing a reduction in pCO 2 (hypocapnia).116 Both the cerebral and
coronary vascular beds are CO 2 sensitive, and a reduction in pCO 2 leads to a reduction
in blood flow to these organs. It is unlikely that the small increase in pO 2 that occurs
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with NBO is large enough to compensate for the reduction in blood flow that is caused
by the resultant hypocapnia.117–119 Thus it is likely that O 2 therapy (the standard of care
for >100 years) may in fact exacerbate the ischemic injury caused by CO to some organ
systems. This may help finally to explain some of the variability seen in clinical trials of
NBO and HBO for CO poisoning.
In the past twenty years, additional mechanisms of CO toxicity that extend
beyond its interaction with hemoglobin (Hgb) have been well elucidated.18,21–
23,47,99,100,103,111,120,121

These extra-hemoglobin effects may not be treatable by O 2

therapy and may further explain why HBO may be detrimental in some cases. The
controversial nature of HBO, and the inadequacy of NBO obviate the need for a new
therapy for CO poisoning that is deployable by first responders, and which is capable of
mitigating the extra-hemoglobin effects of CO. We will herein present initial
examinations into the interactions of high-dose OHCbl and ascorbic acid with CO and
COHgb and the implications for the first ever injectable antidote for CO poisoning.
1.7 Hydroxocobalamin:
Hydroxocobalamin is one of four compounds commonly referred to collectively as
Vitamin B 12 . These are hydroxocobalamin, cyanocobalamin, adenosylcobalamin, and
methylcobalamin (See Figure 1).122,123 What is fascinating about the B 12 group of
compounds (known to chemists as “corrinoids”) is that the central ring structure is nearly
identical to the heme moiety of Hgb. The side chains notwithstanding, the central
“corrin” ring is identical to the porphyrin ring of heme except that it is missing one
carbon and the central metal atom is cobalt instead of iron (See Figure 2).124
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Figure 1: B12 “Corrinoid” family of molecules depicting functional group
differences
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Figure 2: Structural similarities between the porphyrin ring of heme and
the corrin ring of B12. Note the lack of a carbon between positions 5 and
6 on the corrin ring.

18

Indeed, this similarity was exploited in early attempts to produce synthetic O 2
carriers to replace the need for blood products when patients lost large amounts of
blood.125 What is even more fascinating is that OHCbl has been used in Europe for
almost 40 years as a very effective antidote against cyanide poisoning, which often
occurs concomitantly with CO poisoning in structural fires.1 It is given in massive doses
of 5-15 grams per patient with few or no side effects, and no serious adverse events yet
reported. It is safe for use in patients taking antidepressants, as well as in pregnant and
nursing women.126,127 Furthermore, some basic lab research from the late 60’s and early
70’s seemed to indicate that it exhibited limited reactivity with CO under the right
conditions.2 Unfortunately, those results were apparently never followed up on in a
translational way. Those early results indicated that under the right conditions OHCbl
was capable of converting CO into CO 2 , thus rendering it harmless.
Beyond its potential effects directly upon CO (which we will investigate in the
remainder of this paper), OHCbl has been shown to interact with multiple bodily
systems that are involved in CO poisoning. OHCbl has been shown to inhibit certain
forms of nitric oxide synthase, as well as to bind nitric oxide directly.128–132 OHCbl has
also been shown to neutralize peroxide, superoxide, and peroxynitrite, along with other
free radicals in a glutathione sparing fashion and thereby inhibit the damaging effects of
free radical damage (a major component of CO toxicity).129 It has also been shown to
regulate Nfκb and TNFα expression, as well as promote an anti-inflammatory state in
leukocytes (ie macrophages and neutrophils).133–137
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1.8 Hydroxocobalamin and CO:
The first to prove that OHCbl was capable of reacting with CO was Gerhard N.
Schrauzer in 1970.2 He demonstrated in-vitro that under the right conditions OHCbl was
capable of converting CO into carbon dioxide (CO 2 ). He performed the first studies on
the kinetics of the reaction and was the first to propose a mechanism. He also tested
the reaction in the presence of COHgb but was unable to demonstrate decarbonylation
and never published any additional findings on the subject. According to Schrauzer’s
work, he proposed that OHCbl was only capable of reacting with free CO, not bound CO
(as in COHgb). He further proposed that this reaction required two molecules of OHCbl,
one in the III+ oxidation state (OHCbl3+), and one in the reduced II+ oxidation state
(OHCbl2+).
He suggested that the CO bound the OHCbl2+, and then formed a transient biscomplex with the non-reduced OHCbl and via a series of electron transfer steps the CO
was converted to CO 2 in the presence of water while the OHCbl3+ became OHCbl2+ and
the OHCbl2+ became OHCbl1+ (See Figure 3). Unfortunately, this mechanism has not
yet been proven, and indeed our work seems to indicate that a different mechanism
may, in fact, be at work.
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Figure 3: Demonstrates two proposed mechanisms for the reaction of carbon monoxide
(CO) with reduced hydroxocobalamin (OHCbl2+). CO is known to form semi-stable
complexes with transition metals (groups 6-10) in low oxidation states. π-back-bonding
between the filled d-orbitals on the cobalt and the empty anti-bonding π*-orbitals of CO
result in a linear Co-CO bond. This results in a buildup of negative charge on the oxygen
which makes it vulnerable to attack by hydroxide, and leads to formation of a metallocarboxylic acid. This can then be deprotonated ultimately leading to the release of CO2
and leaving the two electrons on the metal, a condition which is thought to be stabilized
by the corrin ring. In one theory, one of the two electrons can then be passed on to an
electron acceptor, such as oxidized hydroxocobalamin (OHCbl3+). In another theory, the
two electrons can be neutralized with two protons to give a metal di-hydride which can
then lose H2.
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Numerous studies have shown that CO can form stable complexes with transition
metals (M) in low oxidation states.73,138–140 The lone pair of electrons on the carbon can
form an σ-bond with the metal. In addition π-back-bonding from the filled d-orbitals on
the metal to the empty anti-bonding π*-orbitals on the CO may occur. This π-backbonding causes a build-up of negative charge on the O 2 , making it more reactive and
allowing interactions with electrophiles. In the case of OHCbl, it is likely that the metalCO complex (M-CO) is formed and then attacked by hydroxide [OH]- to produce
[M-COO-H]- which is then deprotonated to yield [M-CO 2 ]2-. The reaction then continues
with the dissociation of CO 2 , which leaves two electrons on the metal. These electrons
are then passed on to an electron receptor (or receptors).
During the early phases of our work we tested varying amounts of different
reducing agents in an effort to establish what combination would prove most effective.
What we found was that the combination with ascorbic acid appeared to have a
uniquely favorable profile compared with other reducing agents. Even more interesting
was that the reaction proceeded even in the presence of excess amounts of ascorbic
acid. If the mechanism proposed by Schrauzer was correct then the reaction should not
have occurred since all of the available OHCbl would have been reduced already by the
presence of excess ascorbic acid. What we found was that excess concentrations of
ascorbic acid not only allowed the reaction to go forward but apparently enhanced it.
Indeed our chosen concentration of ascorbic acid was nearly eight times the molar
concentration of OHCbl. This finding has led us to propose a second mechanism.
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Ascorbic acid is rather unique in that it behaves much like a vinylogous
carboxylic acid and can therefore donate multiple protons per molecule of ascorbic acid.
OHCbl normally contains a 5,6-dimethylbenzimidazole ribonucleotide tail that is
coordinated to the central cobalt atom in the lower axial position (See Figure 4).
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L-Ascorbic Acid.
This behaves as a vinylogous
Figure 4: Hydroxocobalamin (above).
carboxylic acid. The resonance
Note the –OH group in the upper axial
structures stabilize the conjugate
ligand binding site.
base, and it can also exist in a fully
oxidized form wherein both of the
ring hydroxyl groups are double
bonded oxygens.
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This large and bulky structure means that typically only the upper axial ligand
biding site of OHCbl is available. However, the coordinate covalent bond between the
imino nitrogen of the imidazole ring and the central cobalt can be hydrolytically cleaved
in the presence of an acid or base. It has been previously demonstrated that the
reactivity of OHCbl can be greatly improved in some reactions by switching into what is
known as the base-off form (See Figure 5).131,141–144 Protonation of the imino nitrogen
and cleavage of the coordinate covalent bond between it and the cobalt causes the
benzimidazole base to “swing” out away from the central corrin ring, thus exposing the
lower axial ligand binding site of OHCbl. In this form, there is considerably less steric
hindrance around the active site which may make coordination with CO more favorable.
We propose that once in the base-off form, CO coordinates with the central cobalt [MCO] (See Figure 6).
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Figure 5: Base-Off form of Hydroxocobalamin

Figure 6: Progression from the base-on to the base-off form of
hydroxocobalamin and coordination with CO.
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This allows nucleophilic attack on the carbonyl by the hydroxyl group attached to
the cobalt in the upper axial position, resulting in the formation of a carboxylic acid [MCOO-H]-.
The carboxylic acid deprotonates to form [M-COO]2- which then dissociates to
form [M]2- + [CO 2 ]. From here, the mechanism is less clear. The initial bond with CO
and the dissociation of CO 2 would be expected to transfer two electrons to the cobalt
such that it would wind up in the I+ oxidation state (OHCbl1+). This is an extremely
unstable complex and it is likely that the excess electrons would be transferred to
protons (from water or from ascorbic acid) to form a stable metal dihydride. Alternatively
the metal dihydride may further dissociate with the formation of H 2 gas. There is some
precedent for this reaction mechanism based upon the reaction of CO with other
transition metal complexes, and based upon the reaction of NO with OHCbl and similar
compounds.73,138–140 In a Hgb containing system such as ours, it may also be possible
that the excess electrons are transferred either directly or via a radical to the iron of the
heme moiety on Hgb resulting in the formation of methemoglobin.145 Nevertheless, the
exact mechanism in this specific case remains to be proven.
Based upon Dr. Schrauzer’s work, and based upon the work of others with
similar compounds (such as NO, and CO with other catalysts) we generated our first
hypothesis. It is that, under the right conditions, OHCbl is capable of being used as an
antidote for CO and that, if the reaction occurred as expected, then it should be possible
to monitor it using an artificial lung with very careful monitoring of the CO 2 being
“exhaled” or “out-gassed” by the artificial lung.
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1.9 Basic Approach:
1.9.1 Circulation System:
We used a closed-loop circulation system containing fresh whole human blood
and connected to a hollow-fiber membrane oxygenator to produce COHgb and monitor
the concentration of CO and CO 2 coming from the oxygenator. We verified that we
could change the CO 2 concentration of the blood and detect this as a change in the
gas-out concentration of CO 2 (+/- 0.05% v/v within 2.4 sec) using sensitive gas
monitoring equipment connected to the gas-out port of the oxygenator. Using this
system, we then injected high-dose combinations of OHCbl and ascorbic acid in NS
(0.9% NaCl solution), at three different doses in order to detect any changes in CO 2
concentration in the gas-out flow from the oxygenator.
1.9.2 Raman Analysis:
Due to the complex chemical nature of the compounds involved in this study, it
was critical to be able to demonstrate that we were able to generate the reduced form of
OHCbl and to find a more accurate method of measuring the reactions between OHCbl,
ascorbic acid, Hgb, and CO. We chose to use Resonance Raman (RR) spectroscopy in
order to analyze the compounds we were testing and to monitor the reactions.
RR spectroscopy was first developed in the late 1920’s, and since that time it has
improved dramatically.146 RR spectroscopy analyzes scattered light that has been
passed through, or reflected from, a sample. By using a highly uniform (monochromatic)
light source of a known wavelength (typically a high-powered tunable laser) the light is
directed towards an analyte that may be solid, liquid, or gas. Although the majority of
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the excited photons that enter the sample will pass through unaltered, some of those
photons will strike molecules and be scattered in all directions. Of those photons that
are scattered, most will have the same wavelength as the incident light (i.e., the
wavelength of the laser that generated them). However, some of those scattered
photons will be slightly shifted in wavelength, and it is this shift that RR spectroscopy
detects and uses for analysis.
The shift in wavelength occurs because the photons are temporarily absorbed by
the molecule which changes the vibrational energy of that molecule (typically by
changing the molecular orbital of its electrons). When the photon is reemitted from the
molecule, it may transition to either a higher or lower vibrational energy state than it was
in before it absorbed the photon. The energy that is either absorbed by the photon or
donated from the photon causes a slight shift in the wavelength of that photon that is
then detected by the spectral camera.
Since these spectral shifts are very small and the signals are extremely faint,
they can be very difficult to detect. However, if one knows something about the
chemical structure of the analyte of interest, then it is possible to tune the incident laser
light to match the vibrational frequency of the chemical bonds of interest. By tuning the
laser to the appropriate frequency specific bonds will resonate leading to a million-fold
increase in signal intensity. Likewise, if the sample is an unknown structure then it is
possible to tune the laser over a range of frequencies and note where resonance
occurs. Since specific bond types have specific resonant frequencies it is possible to
then use RR spectroscopy to gain basic structural analysis information, which, when
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coupled with a secondary technology such as mass spec, allows for definitive structural
identification.
Unlike other analytical techniques, RR spectroscopy has the advantage of being
extremely fast, it is non-destructive, and requires only incredibly small sample volumes
for analysis. Compared to other spectroscopic techniques such as infrared (IR) and
absorbance (Abs) spectroscopy, the bands from RR are higher resolution. This is critical
in dealing with combinations of B 12 species and Hgb, since these compounds share
several wavelengths on Abs spec that makes them difficult or impossible to distinguish.
Studies have shown that there are highly characteristic changes that occur in the RR
spectra of carboxylic acids and amines, due to the addition or removal of a proton.
Other studies have also shown that it is possible to monitor changes in the oxidation
state of specific bonds within a molecule due to characteristic changes in the RR
spectrum. Thus, it is possible to monitor ascorbic acid for evidence of both
deprotonation and oxidation, and to monitor OHCbl for evidence of reduction or
oxidation, as well as the binding of CO.
Due to the specificity of RR spectra, all of these reactions can be monitored in
blood since the spectral lines for various Hgb species are distinct from those of OHCbl
and ascorbic acid. The intensity of the peak on RR spectra is proportional to
concentration and thus RR spectra can also be used for quantitation. Although not yet
complete, we are using this technology to quantify the amount of COHgb present in a
sample of blood, and to monitor the rate of change (in real time) both in the presence
and absence of the antidote in order to assess if there is any notable effect. This

30

technology is capable of in-vivo use by directing the RR laser to the sublingual capillary
bed, and we are actively working to develop this technology commercially.
In the present study we used RR spectroscopy to identify the formation and
quantity of OHCbl2+ in our antidote mixture. We also used it to create a reference
standard for quantification of COHgb% in whole blood (for later development of an invivo diagnostic device) and to monitor specific changes in OHCbl, ascorbic acid, and
Hgb.
1.10 Summary of Findings:
Sodium bicarbonate (NaHCO 3 ) reacts with carbonic anhydrase in blood to
produce CO 2 . Therefore, we used an injection of NaHCO 3 as a systems check to verify
that a change in the CO 2 concentration of the blood would be detectable in the gas-out
concentration of CO 2 using our equipment. The specified resolution of our CO 2 detector
was listed as 0.1% (1000ppm) at 1 sample per second. By taking 10 samples per
second, the effective resolution was increased to 0.035% (350ppm). We found that the
average signal variance was around 250ppm during sampling, but that we could reliably
detect a change of >500ppm and thus we set this as our minimum level for significance.
We injected 5mL of a standard 2.5% (25g/L) NaHCO 3 solution and observed the
predicted rapid increase in CO 2 concentration (>2,000ppm increase over baseline) in
the gas-out flow. Two negative controls in blood containing COHgb: normal saline (NS),
and OHCbl alone (without ascorbic acid), produced an increase of less than 250ppm
CO 2 . The third negative control in blood containing COHgb: ascorbic acid (reducing
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agent) produced a median increase in the CO 2 concentration of the gas-out flow of
400ppm over 5 trials.
A fourth negative control: OHCbl and ascorbic acid injected into normal blood
that contained less than 1% carboxyhemoglobin (COHgb), produced a highly variable
increase in the CO 2 concentration of the gas-out flow with a mean value of 1500ppm
over baseline. The reason for this is not yet clear.
The mixture of OHCbl and ascorbic acid, when injected into blood containing
COHgb, caused a significant increase in the CO 2 concentration of the gas-out flow, in
comparison to baseline and negative controls with a median of 1200ppm over baseline.
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Methods
2.1 Materials:
All chemicals and reagents were supplied by Sigma-Aldrich unless otherwise
specified and were of analytical/reagent grade or better. We used the Maquet Pediatric
Quadrox-iD® hollow-fiber membrane oxygenators. For consistency, all tubing and
supplies were also from Maquet Getinge Corp. Roller pump was from Stöckert/Shiley®.
Continuous gas monitoring data were amplified and acquired by an MP150® system
from BIOPAC corp. using AcqKnowledge 4.0 software®. Carbon Dioxide (CO 2 )
concentration was captured by a CO 2 100c module from BIOPAC Corp. Carbon
Monoxide (CO) concentration was captured by a Horiba VIA-510® model CO monitor.
Heat exchanger was a Thermo-Haake model DC 10®. All gases used were supplied by
Airgas International. Gas flow was monitored and maintained by universal flow meters
from Aalborg Instruments Inc. Blood-gas analyses were performed using an OSM3®
and an ABL 725® from Radiometer Copenhagen®.
2.2 Resonance Raman Analysis:
We employed the use of resonance raman (RR) spectroscopy in order to
determine whether we had achieved adequate formation of the reduced form of OHCbl,
as well to monitor the kinetics of the reaction and monitor certain characteristic changes
in Hgb. RR spectra were obtained with 5 mw or less of 406.7 nm laser excitation from a
Coherent Sabre DBW krypton ion laser system. The laser excitation was focused to a
100 micron beam waist onto samples that were contained in melting point
capillaries. The capillaries were subjected to lateral motion to lessen possible photolytic
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effects by the laser excitation. Raman scattering was collected by a Canon 50 mm
f/0.95 camera lens and focused onto a 70 micron entrance slit of a Spex (Horiba) model
1870 0.5 meter spectrograph fitted with interchangeable 1200 and 1800 lines/mm
holographic gratings (Jobin-Yvon/Horiba). The spectrograph was coupled to a Pylon
(Princeton Instruments) liquid nitrogen cooled CCD detector with 400 x 1340 pixel
scanning array. Scans were generally completed in 120 seconds. The scanning and
data acquistion software was Winspec from Princeton Instruments. Data were further
processed by GRAMS/AI version 8 (Thermo Fisher Scientific) and Origin-Pro version
7.5 (OriginLab Corp.).
2.3 Blood Collection:
For each experiment we obtained 600 mL of fresh whole human blood, with
standard consent, from patients seen in our Apheresis clinic and anti-coagulated with
70 mL of CPD-A1 in standard fashion. All patients signed a standard informed-consent
form that allows and acknowledges that blood and tissue taken in our institution may be
used for research/scientific purposes. The head of our institutional review board (IRB)
determined that this study was not “human subject research” and as such not subject to
IRB review since blood was being collected as part of a routine procedure (and not for
this study directly), was permanently de-identified and completely anonymous (no one
involved in this study had contact with patients or patient information). Blood donated
from the apheresis clinic was limited to donors with hemochromatosis, porphyria, and
polycythemia. We used the blood within 72 hours of collection, most often within 24-48
hours following collection.
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2.4 Circulation System:
Figure 7 is an illustration of the closed-loop artificial circulation system that we
used for this study. With each experiment, approximately 150 mL of blood was injected
into the system until it was full, and there was no longer any air visible in any of the
tubing or in the oxygenator. After priming the system with blood the roller-pump was set
to a rate of 250 mL/minute which circulated roughly the entire blood volume about 1.5
times per minute. We incorporated fluid sampling ports with luer-lock adapters and
three-way stopcocks into the circulation pathway to allow for blood sampling and
antidote injection. The CO and CO 2 monitors were set to a sampling rate of 10
samples/second.
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Figure 7: Illustration depicting the closed-loop circulation system
we used for these experiments.
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2.5 Equilibration:
The blood we obtained was venous blood and thus contained a significant
amount of residual CO 2 . Therefore, we provided an initial equilibration period for the
blood to off-load CO 2 under a constant flow of medical grade air (20-22% v/v O 2 ; <400
ppm CO 2 ; 78-80% v/v N 2 ) until a flat and stable baseline of CO 2 was achieved as
indicated by a near-zero slope. Following this equilibration period, a 0.6mL sample was
taken and analyzed for standard electrolyte, blood gas, and oximetry values.
2.6 CO Poisoning:
After baseline data were obtained, the in-flow gas mixture was switched to 6,000
ppm CO in research grade air (0.5838% v/v CO, remainder air) for twenty minutes at a
flow rate of approximately 178 mL/min. A second 0.6 mL blood sample was taken and
analyzed as before. If a value of 50% (+/-5%) carboxyhemoglobin (COHgb) was
established then the in-flow gas mixture was returned to medical grade air at a flow rate
of approximately 178 mL/min. If the COHgb level was too low, then the flow of CO was
maintained at 5-10 minute intervals until the desired level was achieved.
Since the amount of CO 2 produced presumably depended upon the relative
concentration of reduced OHCbl to CO (i.e., COHgb) every attempt was made to stay
between 45-55% COHgb. This was intended to prevent an abnormally high or low
COHgb concentration from independently increasing or decreasing the amount of CO 2
produced. A table of the range of blood gas values for each experiment is provided
(Table 1).
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N
Mean
Std Dev
Std Err Mean
Upper 95%
Mean
Lower 95%
Mean
median

Summary Statistics: Post CO Exposure & Pre-Antidote Injection
HbCO1 FCOHb2 ctHb2
Hctc2 tHb1
pH2
SAT1 pCO22
17
17
17
17
17
17
17
17
52.87
51.86
111.06 34.24 11.26
7.25
97.12
19.26
5.90
5.88
14.53
4.37
1.52
0.11
6.57
0.54
1.43
1.43
3.52
1.06
0.37
0.03
1.59
0.13
55.91

54.88

118.53

36.49

12.04

7.31

100.50

19.54

49.83
52.8

48.83
50.9

103.59
115

32.00
35.3

10.48
11.5

7.20
7.265

93.74
98.7

18.98
19.2

1 - Measurement from OSM3; 2 - Measurement from ABL700

Table 1: Range of captured blood-gas values for the blood used during testing. One
blood sample was taken after the blood was warmed and oxygenated in the closed-loop
circulation system. Following 20 minutes of CO exposure, a second sample was
obtained to ensure that between 45-55% COHgb formation had been achieved prior to
injection of the antidote, and additional time was allowed if necessary. All blood
samples were run on both an OSM3 and ABL 725, from Radiometer Copenhagen. If we
encountered a variance between the values provided by the two instruments of >3% we
automatically tested a second sample. If the variance continued, then the problem was
assumed to be in the blood and the experiment was stopped before antidote injection.
This table represents the final values obtained just prior to injection of the antidote. No
post-injection blood-gas data are available since hydroxocobalamin causes significant
interference with absorbance spectrometry and invalidates the readings.
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2.7 Antidote Creation:
The antidote consists of a mixture of OHCbl and ascorbic acid in NS. Ascorbic
acid is thought to reduce the oxidation state of OHCbl. The reduced form of OHCbl
(OHCbl2+) is extremely reactive toward any potential oxidant, particularly O 2 itself. Thus,
the addition of ascorbic acid to OHCbl had to be carried out in a glove box under
nitrogen environment. To prevent red cell lysis, deoxygenated NS (0.9% NaCl in water,
Baxter, Inc.) was used as the solvent. The NS was deoxygenated by placing it in a
cleaned, sterilized flat-bottomed glass vacuum flask and placed under vacuum for 30
minutes, and then flushed with nitrogen gas while still under vacuum for an additional 60
minutes. Approximately 1 hour prior to injection, the selected amounts of OHCbl and
ascorbic acid were measured and placed into a sterile container with 5 mL of
deoxygenated NS and mixed until fully dissolved. The antidote solution was then
transferred from the sterile mixing container into a 5 mL syringe and placed into the
glove-box airlock under continuous nitrogen flow until it was needed.
2.8 Antidote Injection:
Following adequate formation of COHgb and transition back to medical grade air
the gas-out concentration of CO was monitored until it achieved steady state typically
around 400 ppm. The CO monitoring line was then clamped so that all out-flow gas would
go through the CO 2 monitor in order to allow for accurate measurement of total CO 2 gasout concentration. The CO 2 concentration was monitored for an additional 5 minutes
following clamping of the CO monitoring line to ensure an accurate baseline prior to
antidote administration. At that steady state a 5 mL solution of the antidote was infused
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into the flowing blood. Gas-out concentration of CO 2 was continuously measured at a
sample rate of 10 samples/sec after infusion of the antidote for 30 minutes.
According to the experiments performed by Schrauzer et al. in the 1970’s, two
molecules of OHCbl are required to reduce one molecule of CO. In addition, their work
suggested that the rate of the reaction was partially dependent upon the ratio of
reduced to non-reduced OHCbl. We used to the following calculations to estimate the
concentration needed to achieve 1:1 concentration of CO:OHCbl in our system. Hgb
has an O 2 binding capacity of 1.36-1.37mL O 2 per gram Hgb. The density of O 2 is
.001331 g/mL, and the molecular weight of O 2 is 15.9994 g/mol. Thus, the O 2 carrying
capacity of Hgb is 1.114x10-4 moles of O 2 per gram Hgb if the Hgb is 100% saturated
with O 2 . Since CO and O 2 share the same binding sites, we use the same value.
Therefore, at 50% saturation, the value would be 5.57x10-5 moles of CO per gram of
Hgb. Our system, contained 150 mL of blood, with an average Hgb value of 130 g/L.
Thus the total grams of Hgb in our system are calculated as approximately 19.5 grams.
The total moles of CO at 50% saturation in our system were calculated to be
approximately 1.0862x10-3 moles CO. Multiplying this value by the molecular weight of
OHCbl (1382.82 g/mol) provides us with 1.5 grams of OHCbl needed to provide molar
equivalency for the amount of CO bound to Hgb in blood. Due to the expense and
limited availability of OHCbl, we chose a value of half of this amount as our initial
starting dose.
In total, three doses were chosen: 700 mg of OHCbl with 700 mg ascorbic acid
(1/2 molar equivalency), 300 mg of OHCbl with 300 mg ascorbic acid (1/2 initial), and
300 mg OHCbl with 150 mg ascorbic acid (to evaluate the mechanism). Although the
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precise mechanism of the reaction has not yet been definitively proven, the proposed
mechanism suggests that the rate of reaction is partly dependent upon the ratio of
reduced to non-reduced OHCbl since both may be necessary for the reaction to occur.
Therefore, we chose to evaluate whether or not a change would be observable when
we altered the ratio of ascorbic acid to OHCbl, in addition to any change that might be
observable from altering the dose of OHCbl overall. Thus, the 3 doses chosen were:
700 mg:700 mg, 300 mg:300 mg, and 300 mg:150 mg, as a ratio of OHCbl:ascorbic
acid respectively.
2.9 Controls:
Both positive and negative controls were used in order to minimize the risk of a
type I error. For the positive control, a standard 2.5% solution of sodium bicarbonate
(NaHCO 3 ) in water was used. Following the identical set of experimental procedures
listed above, 5 mL of 2.5% NaHCO3 solution was injected after formation of COHgb
instead of the actual antidote. The gas-out CO 2 concentration was monitored for 30
minutes following injection of the positive control solution
There were three negative controls: deoxygenated NS, ascorbic acid alone, and
OHCbl alone. Following the procedures listed above, either 5 mL of deoxygenated NS
(0.9% NaCl), 350 mg of ascorbic acid alone in 5 mL of deoxygenated NS, or 350 mg of
OHCbl alone in 5 mL of deoxygenated NS were injected into the oxygenator. To
demonstrate the synergy of the combination of ascorbic acid and OHCbl, the 350 mg
OHCbl control injections were followed by injection of 350 mg of ascorbic acid. The gas-
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out CO 2 concentration was monitored for 30 minutes following injection of the negative
control solutions.
2.10 Analysis:
Data from the CO and CO 2 analyzers were routed through the MP150 system and
captured by AcqKnowledge™ 4.0 software. Values were in ppm/minute, plotted over 30
minutes from the time of antidote injection. These values were imported into an Excel™
spreadsheet and analyzed using JMP™ 10 software for statistical analysis and cleanup.
The graphs in Figure 17 were created using JMP 10, and represent the mean values of
the 5 sample runs at each dose in ppm per unit time. Four of the five sample runs at
each dose were paired, using the same unit of blood for each of the three doses tested.
For these four samples the median and interquartile range values for the area under the
curve of each paired data set were analyzed using the Wilcoxon signed-rank test.
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Results
3.1 Resonance Raman Analysis of OHCbl and ascorbic acid:
The RR spectrum of B 12a is dominated by a very large band at 1499 cm-1 that is
due to -C=C- bond stretching in the macrocycle (Fig 8). This indicates that the OHCbl
used for our studies was very pure, and matches published spectra.147 The purity of the
OHCbl was further verified with HPLC-MS (high pressure liquid chromatography and
mass spectrometry) analysis, which also indicated a purity of >99%. Raman analysis of
the L-ascorbic acid used, also indicated high-purity, and provided a strong peak in the
region of 1690 cm-1 which matches published spectra.148,149 The broad band in this
region is due to the v(C=O) stretch of the lacton and disappears upon deprotonation
with the appearance of a new band near 1595 cm-1. The combination of OHCbl and
ascorbic acid showed a loss of the ascorbic acid peak at 1690 cm-1, a loss of intensity of
the 1496 cm-1 peak and formation of strong peaks at 1602 cm-1, 1537 cm-1, and 1352
cm-1. These changes are indicative of the deprotonation of ascorbic acid and the
formation of OHCbl2+.
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Figure 8: RR spectra of OHCbl in NS (a), OHCbl+ascorbic acid in NS (b), and
ascorbic acid in NS (c). Key peaks for OHCbl (a) are 1499 cm-1, 1199 cm-1, and
1163 cm-1. Key peaks for ascorbic acid (c) are 1693 cm-1, 1148 cm-1, and 828 cm-1.
Key peaks for the mixture of OHCbl and ascorbic acid (b) are 1602 cm-1, 1537 cm-1,
1496 cm-1 and 1352 cm-1. The decrease in intensity at 1499 cm-1 with the
appearance or strengthening of the peaks at 1602 cm-1 and 1352 cm-1 are strong
indicators of the formation of OHCbl2+.
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Sodium nitrite (a powerful oxidizing agent that does not interfere with RR
analysis) was added to the mixture of OHCbl and ascorbic acid, in order to oxidize the
OHCbl2+ to OHCbl3+ (Fig. 9). RR analysis shows only a single intense peak at 1500 cm1

with loss of the peaks at 1602 cm-1, 1537 cm-1, and 1352 cm-1, consistent with

oxidation of OHCbl2+ to OHCbl3+. A solution of methylcobalamin was analyzed in order
to look for the types of spectral shifts that might occur with substitutions in the axial
ligands of the cobalamin species. The spectrum of methylcobalamin is remarkably
different from that of OHCbl, with three bands predominating at 1487 cm-1, 1538 cm-1,
and 1591 cm-1. Attempts to alter the spectrum of methylcobalamin by oxidation with
sodium nitrite yielded no detectable spectral changes.

45

Figure 9: RR spectra of OHCbl with ascorbic acid and sodium nitrite (a),
methylcobalamin (b), and methylcobalamin with sodium nitrite (c). Key peaks for
OHCbl with ascorbic acid and sodium nitrite (a) are 1500 cm-1, 1202 cm-1, and 1164
cm-1. Key peaks for methylcobalamin (b) are 1487 cm-1, 1538 cm-1, and 1591 cm-1.
Key peaks for methylcobalamin with sodium nitrite (c) are the same as those for
methylcobalamin alone: 1487 cm-1, 1538 cm-1, and 1591 cm-1.
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3.2 Resonance Raman Analysis of Blood:
Internal standards of fresh whole blood were prepared and analyzed in order to
establish parameters for accurate quantitation and identification of the various states of
Hgb in our samples (Fig. 10). The deoxyhemoglobin (O 2 Hgb% < 6.9%) sample showed
two intense peaks at 1356 cm-1 and 1472 cm-1. The methemoglobin samples had two
intense peaks at 1371 cm-1 and 1563 cm-1. The oxyhemoglobin (O 2 Hgb% = 100%)
samples had two intense peaks at 1377 cm-1and 1639 cm-1. These peaks were all in
agreement with published spectra.150,151 The COHgb (COHgb% > 87%) sample showed
two intense peaks at 1375 cm-1 and 675 cm-1.
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Figure 10: RR spectra of deoxyhemoglobin (a), methemoglobin (b), oxyhemoglobin
(c), and COHgb (d). Key peaks for deoxyhemoglobin (a) are 1356 cm-1 and 1472
cm-1. Key peaks for methemoglobin (b) are 1371 cm-1 and 1563 cm-1. Key peaks for
oxyhemoglobin (c) are 1377 cm-1 and 1639 cm-1. Key peaks for COHgb (d) are 1375
cm-1 and 675 cm-1 (not shown). These were internal standards created in our lab,
and verified using a standard laboratory co-oximeter. This allows for definitive
identification of these species when analyzing a complex matrix or mixed sample.
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Initial scans of a blood sample containing 49.2% COHgb showed a double-peak
at 1359 cm-1 and 1377 cm-1 as well as an intense peak at 1473 cm-1 (Fig. 11). These
peaks are consistent with a mix of deoxyhemoglobin and oxyhemoglobin. It is well
known that the high energy of the RR laser can induce photolysis of CO from Hgb and
this feature has been often utilized to study the kinetics and electronic intermediates of
Hgb and other hemoproteins (such as the cytochromes).53,151,152 Thus, it is likely that
this represents photolyzed COHgb rather than true deoxyhemoglobin. Oscillating the
sample during the scan by the laser, can reduce the photolytic effects and allow for a
true scan of COHgb. This is seen in line (b) with a reduction of the 1359 cm-1 peak and
a new peak at 1375 cm-1. We allowed the sample to settle overnight and then
differentially focused the laser on the red blood cells (RBC’s) and then the plasma. This
indicated the presence of some Hgb, (presumably free Hgb) in the plasma. This also
indicated that the plasma fraction of Hgb was almost entirely oxyhemoglobin, an
unexpected finding considering that this blood contained a significant amount of CO.
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Figure 11: RR spectra of a blood sample containing 49.2% COHgb. The capillary
was placed on its side and the blood was allowed to settle in the capillary overnight
to separate the plasma from the RBC’s. The laser was differentially focused on the
RBC’s and then the plasma. (a) RBC scan without oscillating the sample, (b) RBC
scan with sample oscillation, (c) plasma scan with oscillation. The internal standard
of oxyhemoglobin (d), is placed here for reference comparison.
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3.3 Resonance Raman Analysis of the antidote in poisoned blood:
RR analysis of poisoned blood was taken at two time points following antidote
administration, one at 20 minutes and the second at 70 minutes (Fig. 12). Again, the
blood was allowed to settle and the laser was differentially focused on the RBC’s and
the plasma. The predominant peaks at 1359 cm-1 and 1473 cm-1 in the RBC’s are
indicative of deoxyhemoglobin. This may be true deoxyhemoglobin, or it may be due to
laser photolysis of COHgb. Interestingly, there is no evidence of oxyhemoglobin in the
RBC fraction, as was seen in the same blood prior to antidote administration.
Conspicuously absent from this spectrum are peaks for OHCbl and ascorbic acid
(expected peaks at 1499 cm-1,1602 cm-1, 1537 cm-1, and 1352 cm-1). The plasma
fraction again appears to contain free Hgb. In contrast to the same blood prior to
antidote administration, the free Hgb is now entirely methemoglobin. In this closed
system, therefore, the Hgb species appear to exist only as either
deoxy/carboxyhemoglobin or methemoglobin when exposed to the antidote mixture
dependent on whether the Hgb is free or cellularly bound. These results were entirely
unexpected and at present we cannot explain these findings.
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Figure 12: RR spectra using the same blood shown in figure 11, containing 49.2%
COHgb following antidote administration. After a baseline sample was obtained, the
300mg:300mg antidote mixture was injected and two additional samples were taken
at 20 min and 70 min post antidote injection. The capillary was placed on its side
and the blood was allowed to settle in the capillary overnight to separate the plasma
from the RBC’s. The laser was differentially focused on the RBC’s and then the
plasma. (a) RBC scan at 20 min post antidote injection, (b) RBC scan at 70 min, (c)
plasma scan at 20 min post antidote injection, (d) plasma scan at 70 min post
antidote injection.
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3.4 Control Runs:
We checked the viability of the closed-loop circulation system for detecting
changes in the gas-out CO 2 concentration through the use of a 2.5% NaHCO 3 injection
(Fig. 13). NaHCO 3 reacts vigorously with carbonic anhydrase in blood to produce CO 2 .
We predicted that this rise in CO 2 concentration of the blood would be detectable as a
subsequent rise (>0.1% v/v within 10 sec) in the gas-out concentration of CO 2 . The
2.5% sodium bicarbonate injection resulted in a nearly 3-fold increase over baseline
(from 100 ppm to 2,500 ppm) in 15 seconds in the gas-out CO 2 concentration.
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2.5% Bicarbonate injection response : CO2
Generation vs Time
(mg hydroxocobalamin:mg ascorbic acid)
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Figure 13: Following a warming and equilibration period, 10mL of freshly prepared
2.5% NaHCO3 solution in NS were injected into the system. The line shows the
mean response of the CO2 generated (in ppm) over time. This was performed to
demonstrate the ability of the system to detect changes in the CO2 concentration
when a substance was injected into it that caused a rise in pCO2. This was also
done to demonstrate the graphical appearance of CO2 generation due to an acidbase type reaction.
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As shown in figure 14 we tested each component of the antidote individually
(deoxygenated NS, OHCbl, and ascorbic acid) in order to determine whether any rise in
the gas-out CO 2 concentration was due to an individual component or due to the
combination only. We also evaluated the combination of OHCbl and ascorbic acid in
blood that was essentially free of COHgb to test whether a subsequent rise in the gasout CO 2 concentration was due to a reaction of the antidote with some component of
the blood other than either CO or COHgb.
We used NS as our first negative control since it is non-reactive. The injection of
5mL of deoxygenated NS showed a slight increase in the gas-out CO 2 concentration in
the presence of COHgb with a median value of 250 ppm over a total period of 30
minutes. Injection of 350mg of OHCbl in 5mL deoxygenated NS showed a median
increase of 250 ppm over a total period of 30 minutes. Injection of 350mg ascorbic acid
in 5mL NS showed a median increase in the gas-out CO 2 concentration of 400 ppm
over a total period of 30 minutes in the presence of COHgb. Surprisingly, injection into
normal blood that contained less than 1% COHgb, of 300mg of OHCbl and 300mg
ascorbic acid in 5mL NS also showed a median increase of 1500 ppm over a total
period of 30 minutes in the gas-out CO 2 concentration.
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Control Experiments: CO2 Generation vs Time
(mg hydroxocobalamin:mg ascorbic acid)
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Figure 14: Median response by the four control experiments. The injection of NS
alone and OHCbl alone each showed no response. As expected, the injection of
300mg of ascorbic acid showed a moderate response that was similar (although
less pronounced) to that of the bicarbonate injection. Surprisingly, the injection of
the combination of OHCbl and ascorbic acid into blood that contained <1% COHgb
resulted in a significant increase in CO2 concentration.
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3.5 Serial Injections:
We performed the NS and the OHCbl negative controls in a serial fashion, in
order to assess and demonstrate the unique nature of the combination of ascorbic acid
and OHCbl. After forming COHgb using the closed-loop circulation system we injected
the NS, followed by injection of the OHCbl, and then by injection of ascorbic acid at 30minute intervals. Figure 15 demonstrates the difference in the activity of the mixture of
ascorbic acid and OHCbl (reduced versus non-reduced OHCbl) for reacting with CO invitro. Neither the injection of NS, nor the injection of OHCbl resulted in a significant (i.e.,
<500ppm) change in the gas-out concentration of CO 2 . The subsequent administration
of ascorbic acid, resulted in a 3-fold increase in the gas-out concentration of CO 2 with a
median increase of 1100ppm over baseline. Injection of the solution of pre-mixed
OHCbl and ascorbic acid into blood containing 45-55% COHgb resulted in a 3-4 fold
increase in the gas-out concentration of CO 2 .
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Figure 15: 5 samples were performed by injecting each control solution in a serial or
sequential fashion. Sequential injection of 5mL deoxygenated NS, followed by
350mg OHCbl in 5mL deoxygenated NS, followed by 350mg ascorbic acid in 5mL
deoxygenated NS. The line shows the mean response of the 5 samples in CO2
generated (in ppm) over time. This was performed to demonstrate the unique
synergy of the combination of ascorbic acid with OHCbl as opposed to the lack of
reaction of the individual components.
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We found with some samples that injection of the antidote mixture into blood that
was not poisoned with CO nevertheless resulted in a significant increase in CO 2
concentration. Therefore, we attempted to determine where this CO 2 might be coming
from. In order to assess whether the CO 2 being produced was due to a breakdown
product from the combination of OHCbl and ascorbic acid, we filled our circulating
system with NS and injected the antidote mixture. As shown in figure 16, there was no
detectable increase in the gas-out concentration of CO 2 . To determine whether the CO 2
produced was due to interaction of the antidote with some component of blood we then
performed two serial injections, the first with plasma and the second with packed red
blood cells. Both injections resulted in a rapid and transient rise in the gas-out
concentration of CO 2 . However, in both cases the CO 2 returned to baseline within five
minutes.
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Sequential Events with Circulating Saline:
1) 300:300, 2) 10ccs Plasma, 3) 10ccs RBCs
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Figure 16: Injection of a mixture of 300 mg OHCbl plus 300 mg ascorbic acid in 5mL
of deoxygenated NS into the circulation system which contained only NS instead of
whole blood. Sequential injection of 10 mL plasma followed by 10 mL packed red
blood cells. The line shows the mean response of the 5 samples in CO2 generated
(in ppm) over time. This was performed to demonstrate that the CO2 produced was
not due to a breakdown product of the mixture of OHCbl and ascorbic acid, and to
ascertain whether it might be due to a reaction with some blood component other
than CO.
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3.6 Mean Dose Response:
Figure 17 shows the mean values of CO 2 produced over time according to the
amount of antidote that was injected into the blood. As seen from the graphs, all three
doses resulted in a five to eight-fold increase in the gas-out concentration of CO 2
compared with controls. Also visible in the graph is the difference between the highdose (700 mg:700 mg) and the low-dose (300 mg:300 mg).
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Mean Carbon Dioxide Generation Response at Varied Doses
(mg hydroxocobalamin:mg ascorbic acid)
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Fig 17: N=5 trials of each dose: 700mg hydroxocobalamin with 700 mg ascorbic acid;
300mg OHCbl with 300 mg ascorbic acid; 300mg OHCbl with 150 mg ascorbic acid.
Each line represents the mean response over time and is plotted to show the central
tendency of CO2 generation (in ppm) for each dose mixture over a 30 minute period.
The controls (N=5 for each) were: deoxygenated NS (0.9% NaCl solution), 350 mg
OHCbl in 5mL deoxygenated NS, and 350mg ascorbic acid in 5mL deoxygenated NS.
The control line above represents the aggregate central tendency for all three.
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3.7 Dependent (Paired) Experiments:
Performing three dose-experiments per unit of blood allowed us to collect and
compare paired (dependent) data on the dose-response relationship within the same
unit of blood for each dose for four out of the five samples. We looked at two
dependent mean comparisons: Proportionate Dose and Non-Proportionate Dose. The
doses are displayed in mg of OHCbl: mg of ascorbic acid. In the Proportionate Dose
case, we tested a low dose, 300mg:300mg, to a high dose, 700mg:700mg, from the
same blood donor, and repeated this five times with five unique donors. In the NonProportionate Dose case, we compared 300mg:300mg dose with a 300mg:150mg dose
on blood from the same donor, and repeated this four times with four unique donors.
The area under the curve (AUC) from the time response curves from these samples
was measured, and represents the magnitude of CO 2 generated from the system in
units of ppm-min. The AUC was normalized by extrapolating out 30 min of data from 4
min of actual baseline measurements, and subtracting the 30 min baseline AUC from
the 30 min AUC of the post-antidote curve. Analysis of the differences in the AUC was
performed by Wilcoxon signed-rank test due to the small sample sizes, and compared
against a significance of α = 0.05. The one-sided signed t-test = 6.25, DF = 3 and the
p-value = 0.0041 for the Proportionate Dose Comparison. The Non-Proportionate Dose
Comparison produced a signed t-test = 0.27, DF = 3 and p-value = 0.3125. These
results are displayed in table 2.
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Dose Comparisons

mg OHCbl:mg ascorbic acid
300:300
700:700
Control

Proportionate Doses
(1:1 vs 1:1 Mixtures)

Non-Proportionate
Doses
(1:1 vs 2:1 Mixtures)

Median
Inter-Quartile Range
(ppm-min)
(ppm-min)
35081
34032, 37724
47692
42495, 53806
?
?, ?

% Difference of the Median = 36%
300:300
24384
300:150
34339
Control
?

p-value = 0.0041
22625, 42107
31153, 35145
?, ?

% Difference of the Median = 41%

p-value = 0.3125

Table 2: Paired (dependent) data using blood from the same donor (N = 4). Two
types of dose comparisons:
1) Proportionate dose increase where both the OHCbl and ascorbic acid doses
were increased proportionately.
2) Non-proportionate increases with an increase in the ascorbic acid while keeping
the OHCbl constant.

The area under the curve (AUC) from the dose response over time was measured,
and represents the magnitude of CO2 generated from the system in units of ppmmin.
The proportionate dose comparison produced a signed t-test = 6.25, DF = 3 and
the p-value = 0.0041.
The non-proportionate dose comparison produced a signed t-test = 0.27, DF = 3
and p-value = 0.3125.
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Discussion
4.1 Summary:
The results of this study indicate that the mixture of OHCbl and ascorbic acid in
blood containing COHgb may be capable of converting CO to CO 2 . The magnitude of
this conversion is uncertain, however, and will require further investigation. This is an
important finding with significant clinical implications since both of these compounds are
safe and approved for use in humans even at extremely high doses.1,3 Although both
ascorbic acid and OHCbl are being used increasingly in the settings of trauma, burn,
and smoke inhalation, this is the first study that suggests a novel set of capabilities
when the two are combined at high dose. This study also indicates that these
compounds may be effective whether they are given together or separately but spaced
closely together. The potential to extract CO from the body, by its conversion to CO 2 ,
independently of high-flow or high-pressure O 2 is a novel finding.
4.2 Resonance Raman Analysis:
All corrinoid compounds contain very strong absorption bands in the visible and
near-ultraviolet wavelengths, due to the π-π* electronic transitions.147 Therefore, tuning
the laser to these ranges (i.e. 400-500 nm) produces strong resonance enhancement of
raman bands associated with vibrations of the corrin ring which contains –C=C- bonds
(that contain π-bonding electrons). Cobalt contains valence electrons within the d-orbital
system. Thus changes in the electronic state of the cobalt molecular orbitals (d-d
transitions) may also be detectable by using laser wavelengths in the 476-606 nm
range.153 This range appears to be particularly sensitive to alterations in the lower axial
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ligand (i.e. base-off versus base-on form of OHCbl). Although we have not yet been
able to investigate this ourselves, it would be beneficial in determining the mechanism
of the reaction and demonstrating formation of the base-off form of OHCbl. Several
studies have shown that the spectra of OHCbl3+, OHCbl2+, and OHCbl1+ are distinct,
and that detection of the base-off form of OHCbl is also possible.147,148,153–156
In our studies so far the loss of the 1690 cm-1 peak along with the appearance of
a new peak at 1600 cm-1, (when hydroxocobalamin and ascorbic acid were mixed) were
indicative of deprotonation of the hydroxyl group on the ring structure of ascorbic
acid.149 In the same mixture the decrease in intensity at 1496 cm-1 along with the
appearance of new bands at 1600 cm-1 and 1352 cm-1 indicate successful formation of
OHCbl2+ species in solution.147,148 This also suggests that the 406.7 nm wavelength is
quite sensitive at detecting the π-π* electronic transitions occurring in the corrin
macrocycle due to changes in the oxidation state of the coordinated cobalt and
subsequent delocalization of the additional electrons. Unfortunately, this wavelength
appears to be less sensitive at detecting the Cobalt d-d transitions that have been
shown to accompany alterations in the lower axial ligand, although we are continuing to
study this.
The addition of sodium nitrite (a powerful oxidizing agent that does not interfere
with RR analysis) to the mixture of OHCbl and ascorbic acid, was expected to re-oxidize
the OHCbl2+ to OHCbl3+. RR analysis shows only a single intense peak at 1500 cm1

with loss of the peaks at 1602 cm-1, 1537 cm-1, and 1352 cm-1, consistent with

reoxidation of OHCbl2+ to OHCbl3+. This offers further evidence that we successfully
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formed reduced OHCbl via the addition of ascorbic acid, since we were able to reverse
the spectral changes by addition of an oxidizing agent.
Changes in specific bonds or bond types often result in characteristic changes of
RR spectra. For example, attachment of different ligands at the same site will often shift
the RR spectrum in a characteristic fashion. A shift towards a longer wavelength
(compared with the incident beam) is called a red-shift, and a shift towards a shorter
wavelength is called a blue-shift. In the case of OHCbl, it is possible to study the effects
of differential ligand binding to the central cobalt in the upper axial position (sixcoordinated cobalt) using known compounds such as OHCbl, methylcobalamin, and
adenosylcobalamin. By knowing the properties of these bonds, and whether they are
likely to be electron donating or electron accepting, it becomes possible to look at an
unknown ligand bound to the upper axial position and make some conclusions about its
nature.
We analyzed a solution of methylcobalamin in order to look for the types of
spectral shifts that might occur with substitutions in the upper axial ligand of the
cobalamin species. The binding of the methyl group is much stronger than that of
hydroxide, water, or CO and would therefore be expected to provide quite a different
spectrum. We found that the spectrum of methylcobalamin was, indeed, quite different
from that of OHCbl, with three bands predominating at 1487 cm-1, 1538 cm-1, and 1591
cm-1. The attempts to alter the spectrum of methylcobalamin by reduction with sodium
thiosulfate (a powerful reductant with minimal interference with RR) or oxidation with
sodium nitrite yielded no detectable spectral changes. This provided us with some
valuable information when identifying peaks in the mixture of poisoned blood and the
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antidote since it would allow us to determine not only whether the OHCbl was in the
reduced or oxidized state, but also potentially to determine if there was perhaps a
different ligand bound in the upper axial site.
Most studies involving Hgb and other heme proteins have relied upon lasers with
longer wavelengths closer to the visible spectrum, and near the absorbance maxima of
Hgb around 525 nm. The use of near-UV or deep violet lasers such as the 406.7 nm
Krypton ion laser used in this study is far less common and indeed some species have
never been analyzed using this specific wavelength. Our results show that Hgb is quite
amenable to RR analysis at this wavelength, with clear identification of each of the
primary Hgb species (oxy, deoxy, and met).
The analysis of blood containing 49.2% COHgb was complicated by the
phenomenon of photolysis. COHgb is quite stable under anaerobic or sealed conditions,
allowing us to analyze it both immediately after sampling and several hours to days
later. Since the blood was exposed to a normal partial pressure of O 2 during CO
exposure and prior to sampling, there should be no deoxyhemoglobin present in the
sample (or very little). Therefore, the initial spectra obtained indicates probable
photolysis of COHgb, thereby yielding the spectrum for R-state deoxyhemoglobin. This
problem can be solved by keeping the sample flowing, or by oscillating the sample
rapidly in addition to making the laser focus more diffuse and/or reducing the laser
power. This effect is partly seen with the second scan of the same sample in which the
sample was oscillated during the laser exposure. The decrease in intensity of the 1356
cm-1 peak and the emergence of the 1371 cm-1 peak are indicative of the presence of
COHgb and a reduction in the amount of deoxyhemoglobin being detected. Further
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reducing the laser power, more rapid sample oscillation, and/or use of a pulsatile laser
have been shown to reduce photolysis and should result in a more accurate analysis of
COHgb concentration.
Another fascinating finding with the COHgb sample was the presence of only
oxyhemoglobin in the plasma. While the finding of some amount of free Hgb is quite
common, particularly in blood that has been stored and manipulated, we expected that it
would be a mixture of oxyhemoglobin and deoxy/carboxyhemoglobin. It may be that the
free Hgb is able to dissociate CO more rapidly than cellularly bound Hgb, possibly due
to changes in pH or the microenvironment.
The analysis of the blood containing both COHgb and the antidote mixture
likewise presented some unexpected results. Previous scans using a combination of
OHCbl in unpoisoned blood, and OHCbl + ascorbic acid in unpoisoned blood had
shown that we could clearly detect and distinguish each species in the mixture using our
RR system. Yet when we injected the antidote mixture into poisoned blood (i.e.,
containing COHgb) we lose the RR signal for both OHCbl and ascorbic acid entirely.
Furthermore, in this system we find that the RBC’s contain only
deoxy/carboxyhemoglobin and that the free Hgb is completely converted into
methemoglobin. A recent study from 2008 (and the only one of its kind) indicated that
extremely high doses of OHCbl, like those we are using, seemed to convert
deoxyhemoglobin into methemoglobin.145 However, they only tested free porcine Hgb
and not cellular bound or human Hgb. Our results would appear to corroborate this
finding, although we need to study this further.

69

The finding of increased levels of methemoglobin is perplexing and needs further
study, in part because it runs counter to the currently understood mechanisms of
methemoglobin formation. Methemoglobin is formed when the iron moiety of heme is
converted from Fe2+ to Fe3+ due to loss of an electron. The finding of increased levels of
methemoglobin in the presence of OHCbl would seem to indicate that OHCbl is
somehow removing electrons from Hgb. If this were true, it would be a novel finding
since it is likely proceeding through the action of a radical intermediary.
It had occurred to us that the formation of methemoglobin might be an
explanation for the additional CO 2 concentration we see in the gas-out flow after
injection of the antidote mixture. Since methemoglobin loses its ability to carry O 2 as
well as CO and CO 2 . However, if this were the case then we would have expected that
OHCbl alone would have caused an increase in CO 2 concentration. Yet, as we have
shown, the addition of high-dose OHCbl alone caused almost no change in CO 2
concentration. It was only after the addition of ascorbic acid to the mixture of OHCbl and
blood that we saw the significant increase in CO 2 concentration. This might seem to
suggest that the ascorbic acid is somehow contributing to the formation of
methemoglobin by OHCbl. However, ascorbic acid is a reducing agent not an oxidizing
agent and it has in fact been used as an antidote for methemoglobin.157–159 Therefore, it
seems unlikely that the ascorbic acid is contributing to methemoglobin formation; but it
also begs the question of what is causing methemoglobin formation? Regardless of the
cause, this study also indicates that cellular bound Hgb is relatively protected since
there is no evidence of methemoglobin in the RBC’s. However, there is also no
evidence of oxyhemoglobin in the RBC’s. This may indicate that the conversion of CO
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to CO 2 proceeds through an O 2 radical or some other process that results in stripping of
O 2 from Hgb, leaving only deoxyhemoglobin behind. The formation of the O 2 radical
could also explain the formation of methemoglobin via loss of the heme electron to the
O 2 . All of these questions remain to be explored in more detail.
Since RR analysis is capable of quantitation, we had intended to utilize this for
the purposes of quantifying COHgb and monitoring its decay rate in solution both with
and without the presence of the antidote mixture. This would provide an important piece
of additional information regarding the ability to the antidote to speed up elimination of
CO from Hgb via conversion to CO 2 . The various states of Hgb, particularly oxy, met
and COHgb have some overlap on the RR spectrum. However, by identifying specific
peaks representative of particular Hgb species, it is possible to perform a Gaussian
deconvolution of the relative contribution of each peak to the area under the curve. This
allows for definitive quantitation when compared against reference standards for the
particular RR system being used. The identification of a unique COHgb peak using the
406.7 nm laser is a new and unpublished finding. The photolytic effects of the laser
present challenges in ensuring accuracy of quantification that must be overcome
reliably. Therefore, we are not yet ready to definitively quantify COHgb in these samples
but that work is ongoing.
4.3 Controls:
In the course of these experiments we found that we at times achieved significant
levels of CO 2 when injecting the antidote into blood that we had not poisoned. In some
cases this may have been due to the presence of high baseline levels of COHgb (one
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patient had a baseline of >10% COHgb and thus may have been a smoker). We tried
several different units of blood from different patients and found extreme variability in
the amount of CO 2 that was produced upon addition of the antidote even though the
blood was “unpoisoned.” However, even after flushing the blood under pure O 2 for two
hours, in several cases we still had apparently high levels of CO 2 being produced upon
injection of the antidote. There is some evidence that suggests that CO 2 may be
produced as a degradation product of ascorbic acid and/or Hgb. However, when we
injected the antidote mixture into NS we were unable to detect any change in CO 2
concentration, indicating that no CO 2 was being produced or, at least, not enough to
explain our results. We followed this with injections of plasma and then packed RBC’s
into the antidote mixture. There was a rapid initial spike of CO 2 that quickly diminished
in both cases and was consistent with off-gasing of CO 2 that was already present in the
blood/plasma. In both cases, the CO 2 fell rapidly to zero, instead of holding the
sustained high concentration that we had seen when the antidote was injected into
poisoned blood. This is indicative of a unique reaction that is occurring when the
antidote is injected into whole blood. The CO 2 produced by this reaction is greater than
the sum of the CO 2 produced when any of the components are injected individually, and
is not due to a reaction between the components themselves but clearly relies upon
some factor that is present in the blood. This may be the expected conversion of CO to
CO 2 , but we cannot rule out the possibility that there is another source.
4.4 Antidote Trials:
Our evidence indicates that the combination of OHCbl and ascorbic acid results
in the production of a significant quantity of CO 2 when injected into whole blood, and
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that this reaction goes well beyond a simple acid-base reaction. This suggests that the
conversion of CO to CO 2 by this mixture may be possible. However, the interaction of
the antidote with some other component of blood cannot be ruled out. We found that
OHCbl alone results in little or no CO 2 production that we could detect when injected
into blood containing CO, suggesting limited reactivity although these results were not
conclusive. Its efficacy in terms of other physiologic processes in the face of CO
poisoning has yet to be demonstrated.
4.5 Mechanism:
The mechanism suggested by Schrauzer et al. was that a combination of the
reduced and non-reduced forms of OHCbl allowed this reaction to proceed, but our
evidence does not directly support this theory.2 In our study the concentration of
ascorbic acid was nearly eight times the molar concentration of OHCbl, which should
have been more than sufficient to fully reduce the OHCbl, yet the reaction still went
forward. If, as was suggested, the reaction required both reduced and non-reduced
OHCbl in order to work, then a reduction in the concentration of ascorbic acid should
have resulted in an increase in the area under the curve (AUC). Instead, lowering the
ascorbic acid concentration appeared to decrease the AUC. If the mechanism proposed
by Schrauzer et al. were correct, it might also be reasonable to expect that any reducing
agent would allow for this reaction to proceed, but we have not yet tested this theory.
4.6 Limitations:
This study is limited in that it does not study the kinetics or mechanism of this
reaction directly. While there is strong evidence that the production of CO 2 is from CO,
73

these experiments were only designed to study this indirectly. Whether the additional
CO 2 produced when the antidote mixture is injected is due in whole or in part to the
conversion of CO to CO 2 cannot be conclusively determined from the present study.
In addition, while the delayed mixture of ascorbic acid and OHCbl works in this
artificial system, it is unknown whether this would work in a living system where both
OHCbl and ascorbic acid may be taken up by cells or move into the intracellular space.
CO has many effects on physiologic systems throughout the body. The interaction of
the ascorbic acid/OHCbl mixture with these systems was also not studied here. While
the conversion of CO to CO 2 is promising, it does not directly translate into a clinical
benefit. Therefore, further studies in living mammalian systems are required.
4.7 Future Directions:
4.7.1 The Big Picture:
CO poisoning whether alone or as a component of the broader injury of smoke
inhalation injury, remains a significant public health problem the world over.6 The focus
of the present study was to demonstrate whether or not OHCbl could react with CO in
blood and convert it to CO 2 according to the reaction first worked out by Schrauzer et al.
We recognize that there is more at stake here and that the real value of this antidote lies
not solely in its reactivity with CO directly but, instead, in its other effects. CO overdose
has a myriad of effects in the body. Two specific effects have been well researched and
there is evidence to suggest that these may be potential secondary targets for the
action of this high-dose mixture of OHCbl and ascorbic acid.
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4.7.2 Nitric Oxide:
The production and release of nitric oxide has recently been shown in numerous
studies to be a significant effect of CO and a likely culprit in the wide-ranging effects of
CO toxicity.23,25,96,99,100,160,161 CO causes the release of nitric oxide from the
hemoproteins to which it is normally bound, thus causing a rapid rise in free nitric oxide
levels both intracellularly and extracellularly. At the same time, CO has also been
shown to be capable of activating certain forms of nitric oxide synthase, resulting in an
overall increased production of nitric oxide.79,99 Besides the well-known vasodilatory
effects of nitric oxide, it is also a significant regulatory molecule with multiple effects on
various cellular processes.80 Nitric oxide is also a powerful oxidizing agent and high
levels of it can lead to cellular and DNA damage, thereby causing cell death and
immune system activation.161 The reduced form of OHCbl is significant in this situation
because it has been shown in several studies to be capable of not only scavenging free
nitric oxide (potentially via formation of a nitrosyl derivative), but also of downregulating
several forms of nitric oxide synthase.130,132,162,163 Furthermore, there is both direct and
indirect evidence that properly administered OHCbl can have immunomodulatory effects
on neutrophils and macrophages encouraging an anti-inflammatory state as opposed to
the pro-inflammatory state induced by the presence of high concentrations of nitric
oxide and oxidized lipids.128,129,133–137
4.7.3 Reactive Oxygen Species:
The production of reactive oxygen species is a second major component of CO
poisoning that has recently been demonstrated. Studies have shown that CO is capable
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of inducing the formation of reactive oxygen species
intracellularly.22,25,100,111,115,120,161,164,165 It appears to do this primarily through interaction
with the mitochondria. There are likely several mechanisms at work here. At least one
mechanism involves the conversion of xanthine dehydrogenase into xanthine oxidase
causing the formation of peroxide. Another mechanism is the conversion of elevated
levels of nitric oxide into peroxynitrite (ONOO-) which is a longer lasting and more
potent free radical than nitric oxide itself. However, peroxide and superoxide have also
been shown to be produced as a direct result of excess CO exposure.25,99,100 The
effects of excess levels of free radicals are widespread and include DNA/RNA damage,
lipid peroxidation, cell death and immune system activation, among others. Again, the
reduced form of OHCbl has been shown to be capable of neutralizing these free
radicals and modulating the immune system towards an anti-inflammatory
state.129,162,163,166,167 OHCbl is also essential for DNA formation and repair as well as for
maintaining the ability of the cell to utilize O 2 for aerobic metabolism.
4.8 Conclusions:
This study indicates that the production of CO 2 in whole blood by OHCbl and ascorbic
acid is synergistic. This study also demonstrates that OHCbl2+ can be effectively
produced with the addition of ascorbic acid. Although the non-reduced form of OHCbl is
effective at binding and neutralizing cyanide, the literature suggests that this form is
ineffective at interacting with CO, nitric oxide, or reactive oxygen species. Our research
provides some evidence in support of the improved efficacy and functionality of the
reduced form of OHCbl for use in CO poisoning and/or smoke inhalation injury.
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4.9 More is Needed:
There is still much work to be done to prove the efficacy of the reduced form of OHCbl
as an antidote for CO poisoning as mentioned herein. One method for determining the
precise source of CO 2 production in this case, would be to use labeled CO, as well as
labeled ascorbic acid. The CO 2 produced could then be captured and analyzed to see
whether it was coming from CO or from a breakdown product of ascorbic acid or from
something else. Demonstrating the evolution of labeled CO 2 following addition of
labeled CO would be more precise and definitive. Ultimately, however, the real question
is whether or not OHCbl (reduced or non-reduced) offers neuroprotective and/or
cardioprotective benefits resulting in an improvement in clinical outcomes. This can only
be demonstrated through a clinical trial in animals and then humans. We are actively
engaged in performing animal studies as well as pursuing approval for human trials to
determine the ultimate potential for this antidote as an injectable therapy for CO
poisoning, although the results of these trials are still at least a year away. Even in the
event that this antidote should ultimately prove ineffective or unusable, we sincerely
hope that this work will inspire a new era in the treatment and understanding of CO
poisoning leading ultimately to one or several injectable antidotes as one solution for
this significant global health problem.
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